Conclusions : This meta- analysis shows that regardless of the administration method , TRT is the short-term safety and does not promote prostate cancer development or progression but long-term data are warranted with justifiable end points
Background : Testosterone replacement therapy ( TRT ) is a widely accepted form of treatment worldwide for aging men with late-onset hypogonadism syndrome .
Urologists have been concerned about the possibility of TRT causing prostate cancer .
The aim of this study was to assess the relationship between TRT and prostate cancer .
Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men.
Testosterone undecanoate ( 160 mg/day ) or placebo was given orally in a double-blind fashion for 8 months to 23 middle-aged men without urinary tract symptoms . Testosterone was found to increase the mean prostate volume by 12 % ( P < .012 ) . The treatment suppressed the serum concentrations of sex-hormone-binding globulin and follicle stimulating hormone . The observed decrease in the mean serum concentration of luteinizing hormone was not statistically significant . The serum concentrations of prostate-specific antigen did not change as measured by two different well-vali date d immunometric assays . No changes in micturition habits or urine flow charts were reported
Conclusions : This meta- analysis shows that regardless of the administration method , TRT is the short-term safety and does not promote prostate cancer development or progression but long-term data are warranted with justifiable end points
Background : Testosterone replacement therapy ( TRT ) is a widely accepted form of treatment worldwide for aging men with late-onset hypogonadism syndrome .
Urologists have been concerned about the possibility of TRT causing prostate cancer .
The aim of this study was to assess the relationship between TRT and prostate cancer .